Abstract
PARP inhibitors (PARPi) cause synthetic lethality in BRCA-deficient tumors. Whether specific vulnerabilities to PARPi exist beyond BRCA mutations and ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
